Treatment of Subacute Cutaneous Lupus Erythematosus with Localized Skin Lesions
Subacute cutaneous lupus erythematosus (SCLE) presenting as localized cutaneous lupus erythematosus (CLE) skin lesions represents a defined clinical subset where topical therapy is the cornerstone of initial management.
Clinical Scenario
This protocol applies to patients with subacute cutaneous lupus erythematosus who have localized cutaneous lupus erythematosus skin lesions. Topical corticosteroids are the mainstay in the treatment of localized CLE and are effective across all subtypes, including the subacute form.
Treatment Approach (overview only)
First-line management centres on a topical corticosteroid regimen applied for a limited course. For certain lesion types — particularly active, oedematous presentations — an alternative topical class is also recognised as an initial or second-line option.
Full regimen details, treatment sequence, and duration guidance are available in the complete protocol below.
References
- Topical corticosteroids are the mainstay in the treatment of localized CLE being effective in all subtypes (Figure 1), but only few controlled studies have been published proving their efficacy.
- We recommend topical corticosteroids as first-line treatment for a time limited up to some weeks in all CLE lesions.
- In active, oedematous CLE lesions, particularly on the face, we recommend calcineurin inhibitors (0.1% tacrolimus ointment) as an alternative first-line or as a second-line topical treatment option.
View source ↗